JNCE
Closed
Jounce Therapeutics Inc
1.88
0.00 (0.00%)
Last Update: 05 May 2023 16:30:00
Yesterday: 1.88
Day's Range: 1.88 - 1.88
Send
sign up or login to leave a comment!
When Written:
1.89
Jounce Therapeutics Inc. is a clinical-stage immunotherapy company that develops cancer treatments based on the biology of the immune system. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. Jounce's lead product candidate, JTX-8064, is a monoclonal antibody that targets a protein called LILRB2, which is expressed on immune cells and can inhibit the immune response to cancer. JTX-8064 is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors. Jounce also has several other product candidates in preclinical development, including antibodies that target other immune checkpoints and novel cancer antigens. The company has partnerships with Celgene Corporation and Gilead Sciences to develop and commercialize its immunotherapies.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








